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Abstract
Beneficial effects on body weight of supplementation with BCAA, including leucine, isoleucine, and valine, have been
observed in animal and human studies. However, population-based studies on dietary BCAA intake and body weight are
lacking. The objective of this study was to examine the association between dietary BCAA intake and risk of overweight
status/obesity among multi-ethnic populations. The International Study of Macro-/Micronutrients and Blood Pressure is a
cross-sectional epidemiological investigation in China, Japan, the UK, and the US. The study cohort included 4429men and
women ages 40–59 y who were free of diabetes. Diet was assessed by 4 multi-pass 24-h recalls; data on nutrients
including BCAAwere derived from country-specific food tables. Overweight status and obesity were defined as BMI$ 25
and BMI $ 30 kg/m2, respectively. Multivariable-adjusted OR of overweight status/obesity and 95% CI by quartiles of
BCAA intake were estimated by logistic regression. Mean BCAA intake was 2.6 6 0.6% energy; intake was significantly
lower among Chinese participants and similar among participants from the other 3 countries. Compared with those in the
first quartile, the multivariable-adjusted OR (95% CI) of overweight status from the 2nd to 4th quartiles of BCAA intake
were 0.97 (0.80–1.17), 0.91 (0.75–1.11), and 0.70 (0.57–0.86), respectively (P-trend , 0.01). BCAA intake and obesity
were also inversely associated (P-trend = 0.03). In conclusion, higher dietary BCAA intake is associated with lower
prevalence of overweight status/obesity among apparently healthy middle-aged adults from East Asian and Western
countries. J. Nutr. 141: 249–254, 2011.
Introduction
Overweight status and obesity, escalating health problems
worldwide (1), are major risk factors for coronary heart disease
and associated with higher risk of hypertension, dyslipidemia,
diabetes, certain cancers, and other chronic disorders. Nutrition
is important, along with other lifestyle factors, for prevention
and reduction of excess body weight; diets with higher protein
and lower carbohydrate content have been reported to promote
weight loss with greater loss of body fat and reduced loss of lean
body mass (2–6). BCAA, including leucine, isoleucine, and
valine, are essential amino acids and recent studies support the
idea that they may be responsible for some of the beneficial
effects of high-protein diets. BCAA play an important role in
protein synthesis as well as glucose metabolism, the latter
particularly during periods of restricted energy intake (7–9).
One study in wrestlers found that BCAA supplementation was
more effective in reducing body fat than energy restriction alone
(10) and others have reported beneficial effects on body weight
and body fat among obese individuals (11,12).
Most previous studies on BCAA intake and overweight
status/obesity were limited to obese individuals or involved
specific interventions such as energy restriction with supplemen-
tation (10–16). To our knowledge, no study has assessed this
association in a multi-ethnic population. With its high quality
dietary data, the population-based International Study of
Macro-/Micronutrients and Blood Pressure (INTERMAP) Study
provides a unique opportunity to test the hypothesis that BCAA
intake is inversely associated with overweight status and obesity
across different cultures among apparently healthy adults.
1 Supported by NIH grant no. R21DK073812 and INTERMAP was supported by
NIH grant no. R01HL50490.
2 Author disclosures: L. Qin, P. Xun, D. Bujnowski, M. L. Daviglus, L. Van Horn, J.
Stamler, and K. He, no conflicts of interest.
3 These authors contributed equally to this manuscript.
8 Members of the INTERMAP Cooperative Research Group can be found in the
following: Journal of Human Hypertension (2003) 17, 591–608. doi:10.1038/sj.
jhh.1001603. Available at: http://www.nature.com/jhh/journal/v17/n9/full/1001603a.
html.
* To whom correspondence should be addressed. E-mail: kahe@unc.edu.
ã 2011 American Society for Nutrition.
Manuscript received July 1, 2010. Initial review completed August 12, 2010. Revision accepted October 26, 2010. 249
First published online December 15, 2010; doi:10.3945/jn.110.128520.
Methods
Design and participants. INTERMAP is an international cross-
sectional epidemiological investigation involving 4680 men and women
ages 40–59 y from 17 randomly selected diverse population samples in
Japan (4 samples, n = 1145), the People’s Republic of China (3 samples,
n = 839), the UK (2 samples, n = 501), and the US (8 samples, n = 2195).
The study received institutional ethics committee approval for each site
and all participants provided written informed consent.
Details of the INTERMAP Study have been described (17–19).
Briefly, each participant visited the local INTERMAP research center 4
times: twice on consecutive days and twice on consecutive days ~3 wk
later. Dietary data on all foods, beverages, and supplements consumed
were collected by trained and certified dietary interviewers at each visit
using an in-depth, multiple-pass, 24-h recall method that has been
described in detail (17,20). Nutrient intakes were derived from country-
specific food tables compiled and standardized by the Nutrition
Coordinating Center in Minneapolis, MN, and INTERMAP nutrition-
ists for each country (21). Nutrients were expressed as energy density (%
energy) in the present study. In addition, interviewer-administered
questionnaires were used to obtain data on demographic factors and
other potential confounders, as described elsewhere (18).
Two timed 24-h urine specimens, bracketed by the first and second
pair of 24-h recalls, respectively, were used to measure sodium,
potassium, calcium, urea nitrogen (an index of total protein intake),
and other metabolites. Specimens were frozen, shipped periodically to
the Central Laboratory in Leuven, Belgium, and analyzed using methods
and equipment described previously (18) under strict internal and
external quality control. Pearson correlation coefficients between
urinary and dietary nutrient values, similar for men and women, were
0.42 for sodium (P , 0.01), 0.55 for potassium (P , 0.01), and 0.51
for dietary protein and urinary urea nitrogen (P , 0.01) (17).
Overweight status and obesity definitions. Height and weight
without shoes were measured at the first and 3rd visits using methods
and equipment described previously (18). BMI was defined as weight in
kilograms divided by the square of height in meters (kg/m2); the mean
of these 2 values was used. Overweight status was defined as BMI $
25 kg/m2 and obesity as BMI $ 30 kg/m2 (22).
Of 4680 participants, 251 were excluded for diabetes diagnosis
or treatment or extreme daily energy intake [,800 kcal (3349 kJ) or
.5000 kcal (20,934 kJ) for men; ,600 kcal (2512 kJ) or .4000 kcal
(16,747 kJ) for women]. Hence, 4429 participants (822 in China, 1106 in
Japan, 492 in the UK, and 2009 in the US) were included in these analyses.
Statistical analyses. Mean values for demographic and other risk
factors, urinary measures, and dietary factors were compared across 4
quartiles of BCAA intake using ANOVA or chi-square tests as appropriate.
Because partial correlation analysis showed a very high correlation
between BCAA and total protein intake (r = 0.98) and nutrient densities
can help to reduce the likelihood of multicollinearity (23), BCAA intake
was expressed as a percentage of total protein intake (r = 0.19). Logistic
TABLE 1 Characteristics of INTERMAP Study participants by quartile of BCAA intake1
Variable
Quartiles of BCAA (% total protein intake)
1 2 3 4 P2
Participants, n 1107 1107 1108 1107
BCAA, % total protein intake 16.4 6 0.4 17.1 6 0.1 17.5 6 0.1 18.1 6 0.4
Age, y 49.0 6 5.5 49.2 6 5.3 48.7 6 5.6 49.3 6 5.4 0.11
Male, % 43.1 46.6 53.7 55.6 ,0.01
Country, %
Japan 16.1 25.9 32.9 25.0 ,0.01
China 31.6 10.3 10.7 21.7
UK 8.9 9.9 12.7 12.8
US 43.4 53.8 43.8 40.5
BMI, kg/m2 25.9 6 5.1 26.7 6 5.5 26.2 6 5.1 25.8 6 5.6 ,0.01
Physical activity, h/d 3.6 6 3.6 3.2 6 3.4 3.3 6 3.5 3.8 6 3.7 ,0.01
Current smoker, % 29.8 24.5 21.2 19.3 ,0.01
Urinary biomarkers
Urea nitrogen, g/24 h 8.8 6 2.6 9.1 6 2.7 9.2 6 2.6 9.1 6 2.9 ,0.01
Sodium, mmol/24 h 199.6 6 85.8 178.4 6 65.6 175.0 6 65.8 168.3 6 66.3 ,0.01
Potassium, mmol/24 h 50.1 6 19.7 52.9 6 18.8 53.7 6 19.2 55.1 6 21.5 ,0.01
Sodium/potassium 4.7 6 2.8 3.8 6 1.8 3.6 6 1.7 3.5 6 1.7 ,0.01
Calcium, mmol/24 h 4.2 6 2.0 4.1 6 2.0 4.2 6 2.0 4.4 6 2.0 0.06
Daily nutrient intake
Total protein,% energy/d 13.8 6 2.9 15.2 6 2.9 15.6 6 3.0 15.6 6 3.0 ,0.01
Animal protein 6.3 6 4.2 8.8 6 3.6 9.2 6 3.6 9.0 6 4.1 ,0.01
Vegetable protein 7.4 6 2.6 6.3 6 2.0 6.3 6 1.9 6.5 6 2.2 ,0.01
Total fat, g/d 25.8 6 8.2 29.5 6 7.8 29.6 6 7.7 28.6 6 8.1 ,0.01
SFA 7.5 6 3.3 9.1 6 3.4 9.3 6 3.5 9.4 6 4.0 ,0.01
MUFA 9.7 6 3.4 11.0 6 3.2 10.9 6 3.1 10.5 6 3.0 ,0.01
PUFA 6.5 6 2.2 6.8 6 2.2 6.7 6 2.0 6.2 6 1.9 ,0.01
Cholesterol,3 mg /1000 kcal 110.6 6 72.9 144.0 6 69.9 151.4 6 72.6 143.3 6 76.2 ,0.01
Total carbohydrate, g/d 55.9 6 11.4 51.8 6 9.7 52.1 6 8.8 54.1 6 9.8 ,0.01
Starch, g/d 36.5 6 16.8 29.7 6 12.2 30.9 6 11.7 33.5 6 15.2 ,0.01
Estimated total sugar, g/d 14.2 6 6.1 11.0 6 4.8 10.9 6 4.6 11.1 6 4.8 0.86
Energy, Mcal/d 2.2 6 0.6 2.2 6 0.6 2.1 6 0.6 2.1 6 0.6 0.08
1 BCAA intake was expressed as percent total protein intake; all values are unadjusted mean 6 SD, unless indicated.
2 P are for differences across quartiles of BCAA intake.
3 1 kcal = 4.18 kJ.
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regression was used to estimate the OR and 95% CI of overweight status
and obesity by quartiles of BCAA intake. Wald’s Z test was used to test for
cross-region or cross-country heterogeneity of findings and assessed by
addition of interaction terms to the model. Correlation analysis was
performed to assess the association of BCAA and BMI with dietary and
nondietary factors. Potential confounders were selected based on this
correlation analysis and the existing literature. OR and 95% CI for
overweight status and obesity were calculated in 3 models: model
1 controlled for age, gender, and country; model 2 additionally controlled
for employment status, physical activity, smoking status, special diet, total
energy intake, total available carbohydrate, and saturated fat intake;
model 3 further adjusted for total protein intake. Continuous BCAA
(actual value) was used to examine possible linear trends. In addition,
analyses were performed within countries and then overall OR and 95%
CI were estimated by pooling data and weighting by inverse of variance
(24). P-values were 2-sided with P # 0.05 considered significant. SAS
version 9.1.3 (SAS Institute) was used for analyses. Unless noted otherwise,
values in the text are means 6 SD.
Results
BCAA intake was 2.6 6 0.6% energy for the 4429 participants;
intake (2.1 6 0.4% energy) was significantly lower among
Chinese participants and similar across the other 3 countries
(2.7–2.8% energy). BMI was significantly lower among Chinese
and Japanese participants (23.16 3.3 kg/m2 and 23.46 2.9 kg/m2)
compared with participants from the UK (27.46 4.6 kg/m2) and
US (28.66 5.8 kg/m2). The prevalence of overweight status was
25.3, 26.3, 69.3, and 70.2% among participants from China,
Japan, the UK, and the US, respectively. Prevalence of obesity
was 1.9, 3.4, 22.4, and 33.3% across the 4 countries, respec-
tively. Participant characteristics are presented by quartile of
BCAA intake (Table 1). Compared with those in the first quartile
of BCAA intake, participants in the 4th quartile were more likely
to be male and less likely to be current smokers and had higher
total protein, animal protein, and fat intake and lower carbo-
hydrate, starch, and total energy intake.
With adjustment for potential dietary and nondietary con-
founders (age, gender, country, employment status, physical
activity, smoking status, special diet, and intakes of total energy,
total carbohydrate, saturated fat, and total protein), BCAA
intake was inversely related to BMI and overweight status. The
multivariable-adjusted OR of overweight status was 0.70 (95%
CI = 0.57–0.86; P-trend , 0.01) for the 4th quartile of BCAA
intake compared with the first (Table 2). To account for
variation by location, we analyzed data by country and then
pooled the results with meta-analysis weighted by the inverse of
variance. The results did not change appreciably (Table 2).
Because of the low prevalence of obesity in China (1.9%) and
Japan (3.4%), we examined the association between BCAA and
obesity only among participants from the UK and the US.
Multivariable adjusted OR of obesity were 0.75 (95% CI =
0.58–0.98; P-trend = 0.03) for the 4th quartile of BCAA intake
compared with the first. A significant inverse association
prevailed for the Western countries and for the UK separately.
For the US, the inverse direction remained, but the trend became
nonsignificant (P-trend = 0.12) (Table 3).
To test the robustness of our main findings, we conducted 2
sensitivity analyses. First, when we replaced total protein intake
with urinary urea nitrogen in model 3 (Tables 2 and 3), the
inverse associations were essentially the same. Second, when we
replaced total protein intake with the other 17 of 20 naturally
occurring amino acids, the inverse associations remained.
TABLE 2 Multivariable-adjusted OR and 95% CI of overweight status by quartile of BCAA intake1–3
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend
Japan + P.R. China
Participants, n 483 481 483 481
Overweight participants, n 134 146 132 89
Median intake, % total protein intake 16.35 17.11 17.54 18.10
Model 1 1.00 1.11 (0.84, 1.46) 0.95 (0.71, 1.26) 0.57 (0.42, 0.78) ,0.01
Model 2 1.00 1.15 (0.86, 1.53) 1.07 (0.79, 1.44) 0.71 (0.51, 0.98) 0.12
Model 3 1.00 1.13 (0.84, 1.51) 1.03 (0.77, 1.40) 0.68 (0.49, 0.95) 0.08
UK + USA
Participants, n 626 625 625 625
Overweight participants, n 436 434 442 440
Median intake, % total protein intake 16.65 17.10 17.47 17.97
Model 1 1.00 1.04 (0.82, 1.33) 1.18 (0.92, 1.52) 1.16 (0.91, 1.49) 0.18
Model 2 1.00 0.96 (0.75, 1.24) 1.03 (0.80, 1.33) 0.98 (0.76, 1.28) 0.99
Model 3 1.00 0.89 (0.69, 1.14) 0.89 (0.68, 1.15) 0.81 (0.61, 1.06) 0.09
Overall
Participants, n 1109 1106 1108 1106
Overweight participants, n 570 580 574 529
Median intake, % total protein intake 16.60 17.11 17.50 17.99
Model 1 1.00 1.08 (0.90, 1.30) 1.08 (0.90, 1.30) 0.88 (0.73, 1.06) 0.15
Model 2 1.00 1.02 (0.85, 1.24) 1.00 (0.83, 1.22) 0.80 (0.66, 0.98) 0.04
Model 3 1.00 0.97 (0.80, 1.17) 0.91 (0.75, 1.11) 0.70 (0.57, 0.86) ,0.01
Model 3* 1.00 0.99 (0.81, 1.20) 0.96 (0.78, 1.18) 0.80 (0.64, 0.99) ,0.01
1 BCAA intake was expressed as percent protein intake; data are OR and 95% CI unless otherwise indicated.
2 Model 1: adjusted for age, gender and country. Model 2: additionally adjusted for employment status, physical activity, smoking status, special diet and intakes of total energy
intake, total available carbohydrate, and saturated fat. Model 3: additionally adjusted for total protein intake. Model 3*: estimated odds ratios within countries and calculation of
overall odds ratios using meta-analysis weighted by inverse of variance; adjustment for the same covariates as in model 3.
3 P-values for the differences of OR of overweight status between Eastern and Western countries for the 3 higher quartiles are 0.40, 0.87, and 0.06, respectively.
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Discussion
In this international, population-based, cross-sectional study,
dietary intake of BCAAwas inversely associated with prevalence
of overweight status among apparently healthy middle-aged
adults from both East Asian and Western countries and with
prevalence of obesity in Western countries.
Our findings are generally consistent with previous animal
and human studies. Animal studies found that rats fed whey
protein (with 50–75% higher leucine content than other
common food proteins) had significantly lower body weight
and fat mass gain compared with rats fed red meat or casein
(25,26). In other animal studies, leucine supplementation
significantly decreased body weight in obese mice (15,16) and
body fat in rats under food restriction (13) but had no weight
reduction effect in normal-weight mice (16). The magnitude of
weight loss among rats consuming a high-protein diet was
similar to that achieved with leucine supplementation in obese
mice (13). Thus, leucine or BCAA were suggested to be
responsible for the potential beneficial effects of high-protein
intake on body weight. In humans, most randomized controlled
trials (2–6) reported that diets high in protein significantly
lowered body weight in obese individuals, although 1 trial
reported no independent effect of diet composition (27). BCAA
intake was found to reduce body weight and body fat in
intervention studies (10–12). In a short-term study, 25 wrestlers
consumed 1 of 3 energy-restricted diets comprised of high
protein, high BCAA, or low protein (10). Those consuming the
high-BCAA diet had the greatest weight loss (24.0 kg; P, 0.05)
and decline in body fat percent (217.3%; P , 0.05) and a
significant reduction in abdominal visceral adipose tissue
(234.4%; P , 0.05) (10).
Several potential mechanisms may account for the inverse
association between BCAA intake and body weight; animal
studies provide some evidence that leucine may increase energy
expenditure. One study using mice as subjects found that leucine
supplementation was not associated with weight gain in obese
mice with increased food intake (16). Leucine supplementation
was also found to stimulate an increase in plasma leptin, an
adipose-derived hormone regulating energy intake and expen-
diture, and leptin levels were reduced by 40% in rats fed a
leucine-deficient meal (28). Exogenous leptin administration can
suppress appetite and food intake, resulting in decreased body
weight in rats (29,30). Some animal studies using rats or mice
have found that leucine supplementation also increased activity
of mammalian target of rapamycin, another major regulator of
energy balance (31), and consequently lowered body weight
(15,16,32).
Another possible mechanism for the effect of BCAA on body
weight is improved glucose tolerance, because impaired glucose
tolerance (IGT) is suggested to be a cause of obesity (33).
Although data on IGT’s possible role in obesity development are
limited, 1 human study found that higher intra-abdominal
adiposity was an independent risk factor for IGT among
Japanese Americans (34). At present, conflicting data exist on
the role of BCAA as a mechanism for this association. Results of
1 study indicate that rats consuming a high-fat, high-BCAA diet
developed insulin resistance (35). Similar findings have been
reported in nonobese humans (36). Conversely, increased leucine
intake prevented high-fat diet-induced hyperglycemia in obese
mice (16,37). Additionally, leucine was found to stimulate
insulin release from the pancreas, thereby decreasing blood
glucose (38,39). Isoleucine also has a hypoglycemic effect via an
insulin-independent pathway (40,41). Although the beneficial
TABLE 3 Multivariable-adjusted OR and 95% CI of obesity in the UK and US by quartile of BCAA intake1–3
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend
UK
Participants, n 123 123 123 123
Obese participants, n 32 25 26 27
Median intake, % total protein intake 16.67 17.19 17.58 18.02
Model 1 1.00 0.66 (0.36, 1.21) 0.70 (0.38, 1.28) 0.73 (0.40, 1.34) 0.15
Model 2 1.00 0.65 (0.35, 1.23) 0.67 (0.35, 1.27) 0.69 (0.35, 1.35) 0.16
Model 3 1.00 0.58 (0.31, 1.10) 0.52 (0.27, 1.03) 0.52 (0.26, 1.06) 0.04
US
Participants, n 503 502 502 502
Obese participants, n 158 168 170 172
Median intake, % total protein intake 16.65 17.09 17.44 17.95
Model 1 1.00 1.10 (0.84, 1.43) 1.12 (0.86, 1.45) 1.14 (0.88, 1.49) 0.24
Model 2 1.00 0.98 (0.75, 1.29) 0.93 (0.70, 1.22) 0.92 (0.70, 1.21) 0.63
Model 3 1.00 0.94 (0.71, 1.23) 0.84 (0.63, 1.11) 0.80 (0.60, 1.07) 0.12
Overall
Participants, n 626 625 625 625
Obese participants, n 190 193 196 199
Median intake, % total protein intake 16.65 17.10 17.47 17.97
Model 1 1.00 1.03 (0.81, 1.31) 1.05 (0.83, 1.34) 1.08 (0.85, 1.37) 0.55
Model 2 1.00 0.94 (0.74, 1.21) 0.91 (0.71, 1.17) 0.89 (0.69, 1.15) 0.40
Model 3 1.00 0.88 (0.69, 1.13) 0.80 (0.62, 1.04) 0.75 (0.58, 0.98) 0.03
Model 3* 1.00 0.87 (0.77, 0.99) 0.78 (0.60, 1.01) 0.75 (0.58, 0.98) 0.03
1 BCAA intake was expressed as percent protein intake; data are OR and 95% CI unless otherwise indicated.
2 Model 1: adjusted for age, gender, and country. Model 2: additionally adjusted for employment status, physical activity, smoking status, special diet and intakes of total energy
intake, total available carbohydrate, and saturated fat. Model 3: additionally adjusted for total protein intake. Model 3*: estimated OR within countries and calculation of overall OR
using meta-analysis weighted by inverse of variance; adjustment for the same covariates as in model 3.
3 P are for differences in OR of obesity between the UK and US for the 3 higher quartiles are 0.19, 0.23, and 0.19, respectively. None of the quadratic trends are significant.
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effect of increased BCAA intake on body weight through
improved glucose metabolism may be only modest in magni-
tude, it could be of public health significance because of the high
prevalence of IGT in overweight and obese individuals (42).
BCAA intake in the INTERMAP population was consistent
with that found in other study populations. For example, in
intervention studies on adult women ages 40–56 y, mean BCAA
intake in the control group was ;10 g/d (11,12). In addition, a
study using stable isotopes to measure whole-body leucine
metabolism reported that daily leucine intake was ;6 g/d (43),
similar to that found in our study (6.1 6 2.0 g/d). Because long-
term protein intake of 1.2–2.0 g/kg body weight appears to exert
no harmful effect on renal function (11), increased BCAA intake
(e.g. to 20 g/d) apparently would not be harmful to health.
The cross-sectional design of the INTERMAP Study limits
inferences as to the causal relationship between BCAA intake
and risk of overweight status/obesity. To our knowledge, how-
ever, this is the only population-based study that has examined
this issue. It adds evidence to existing literature that significant
inverse associations between BCAA intake and overweight
status may explain at least partially the weight loss effect of
high-protein diets reported by previous intervention studies
(2–6).
In conclusion, we found significant inverse associations between
BCAA intake and overweight status/obesity. Our findings sug-
gest that weight loss induced by a high-protein/low-carbohydrate
diet may be partially explained by BCAA intake. Further studies
are needed to investigate this long-term association and to deter-
mine a potential causal relationship.
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